Ovali Fahri, Gursoy Tugba, Sari Ilkay, Divrikli Demet, Aktas Alev
Neonatal Intensive Care Unit, Zeynep Kamil Maternity and Children's Training and Research Hospital, Istanbul, Turkey.
Pediatr Int. 2012 Feb;54(1):60-3. doi: 10.1111/j.1442-200X.2011.03458.x. Epub 2011 Oct 17.
Neonates are at high risk for nosocomial infections due to multidrug-resistant pathogens. The use of β-lactamase inhibitors in combination with β-lactam antibiotics broadens the antimicrobial spectrum. Cefoperazone/sulbactam is used in children but there are limited data on its usage in neonates. The purpose of the present study was therefore to evaluate the use of cefoperazone/sulbactam in the treatment of neonatal infections caused by multidrug-resistant pathogens.
The records of neonates who were hospitalized and who received cefoperazone/sulbactam were reviewed.
There were 90 infants who received cefoperazone/sulbactam. A pathogen could be isolated in 41 (45.6%) of the infants. In total, 17.1% of isolated pathogens were resistant to cefoperazone/sulbactam. Side-effects were seen in four of the infants. Two infants had cholestasis, one infant had neutropenia and one had superinfection with candida.
Cefoperazone/sulbactam can be used in the treatment of nosocomial infections caused by multidrug-resistant pathogens in neonates.
由于多重耐药病原体，新生儿发生医院感染的风险很高。β-内酰胺酶抑制剂与β-内酰胺抗生素联合使用可拓宽抗菌谱。头孢哌酮/舒巴坦用于儿童，但关于其在新生儿中的使用数据有限。因此，本研究的目的是评估头孢哌酮/舒巴坦在治疗由多重耐药病原体引起的新生儿感染中的应用。
回顾了住院并接受头孢哌酮/舒巴坦治疗的新生儿的记录。
有90名婴儿接受了头孢哌酮/舒巴坦治疗。41名（45.6%）婴儿中可分离出病原体。总共17.1%的分离病原体对头孢哌酮/舒巴坦耐药。4名婴儿出现了副作用。2名婴儿有胆汁淤积，1名婴儿有中性粒细胞减少，1名婴儿有念珠菌二重感染。
头孢哌酮/舒巴坦可用于治疗新生儿由多重耐药病原体引起的医院感染。
